Sugi Predict

Sugi Predict / Compounds / SCHEMBL1929031

SCHEMBL1929031

SCHEMBL1929031

CN1CCN(c2ccccc2Br)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2C P18825 1/20 0.60
▸ DRD2 P14416 3/20 0.56
▸ DRD3 P35462 3/20 0.56
▸ LMNA P02545 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ NCF1 P14598 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ HTR6 P50406 2/20 0.48
▸ HTR1A P08908 4/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ ADRA1B P35368 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28235242 0.89 MGLL (0.46) ADRA2CDRD2DRD3LMNAKMT2A
SCHEMBL27926749 0.89 MGLL (0.46) ADRA2CDRD2DRD3LMNAKMT2A
SCHEMBL11087855 0.89 ADRA2C (0.53) ADRA2CDRD2DRD3LMNAKMT2A
SCHEMBL11093625 0.81 MAPK1 (0.48) ADRA2CDRD2DRD3LMNAKMT2A
SCHEMBL30263414 0.80 KEAP1 (0.48) KMT2AMAPK1NCF1EGFRMAPT
SCHEMBL29763197 0.80 KEAP1 (0.54) KMT2AMAPK1EGFRMAPTHTR6
SCHEMBL3975556 0.80 KEAP1 (0.54) KMT2AMAPK1EGFRMAPTHTR6
SCHEMBL570340 0.80 KEAP1 (0.48) KMT2AMAPK1NCF1EGFRMAPT
SCHEMBL3021427 0.78 KEAP1 (0.57) KMT2AMAPK1EGFRMAPTHTR1A
SCHEMBL424507 0.77 DRD2 (0.75) ADRA2CDRD2DRD3LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 — — US disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 — — US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 — — US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 — — US disclosed
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 — — EP disclosed
US-9926286-B2 Vortioxetine intermediate and synthesis process thereof SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) 2018-03-27 — — US disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 — — EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 — — EP disclosed
CN-104093715-B 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives 埃科特莱茵药品有限公司 2017-04-26 — — CN disclosed
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 — — EP disclosed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 — — EP disclosed
US-20030232841-A1 Heterocyclic carboxamides PFIZER INC 2003-12-18 — — US disclosed
US-6602874-B2 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated PFIZER INC. 2003-08-05 — — US disclosed
US-6537995-B2 Selective serotonin receptor agonists and antagonists used to treat migraines, depression, anxiety and schizophrenia; sertraline PFIZER INC. 2003-03-25 — — US disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 — — WO disclosed
EP-0957099-B1 Heterocyclic carboxamides PFIZER PROD INC (US) 2002-11-20 — — EP disclosed
US-20020002168-A1 Heterocyclic carboxamides HOWARD HARRY R (US) 2002-01-03 — — US disclosed
US-20010041705-A1 Heterocyclic carboxamides HOWARD HARRY R (US) 2001-11-15 — — US disclosed
US-6277852-B1 FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS PFIZER INC 2001-08-21 — — US disclosed
EP-0957099-A2 Heterocyclic carboxamides Pfizer Products Inc. (US) 1999-11-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002168-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R ADRA2C 266/4885DRD2 139/4885DRD3 112/4885
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 ADRA2C 2739/4885DRD2 4463/4885DRD3 4251/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 ADRA2C 2739/4885DRD2 4463/4885DRD3 4251/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 ADRA2C 2739/4885DRD2 4463/4885DRD3 4251/4885
US-20030232841-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R ADRA2C 266/4885DRD2 139/4885DRD3 112/4885
US-20010041705-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R ADRA2C 266/4885DRD2 139/4885DRD3 112/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 ADRA2C 2739/4885DRD2 4463/4885DRD3 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.